title: Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement.
abstract: In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.
authors.affiliation: Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Hirsh
authors.affiliation: Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York.
authors.forename: Nathaniel R
authors.initials: NR
authors.lastname: Smilowitz
authors.affiliation: Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Rosenson
authors.affiliation: Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Valentin
authors.initials: V
authors.lastname: Fuster
authors.affiliation: Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Electronic address: lsperli@emory.edu.
authors.forename: Laurence S
authors.initials: LS
authors.lastname: Sperling
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D015897:Comorbidity; D004359:Drug Therapy, Combination; D019983:Guideline Adherence; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008019:Life Style; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012959:Socioeconomic Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: adherence; ezetimibe; low-density lipoprotein cholesterol; secondary prevention; statin therapy